Sanil Bhatia

This study shows HDAC6 inhibition enhances anti-tumoral immune responses and chemosensitivity in myeloid leukemia cells by upregulating RNase T2 and improving chromatin accessibility.

This paper introduces a C-terminal HSP90 dimerization inhibitor, VWK147, which induces cell death in cisplatin-resistant cancer cells and synergizes with mTOR inhibition to enhance therapeutic efficacy.

The paper identifies non-charged analogs of the inhibitor 7.44 that show improved antiproliferative effects against RUNX1-ETO positive cells.

This study identifies H1-0 as a mediator of ETV6::RUNX1-induced quiescence in BCP-ALL preleukemic cells and suggests HDACi treatment as a potential therapeutic approach.

This study develops a bipyrimidineamide-based α-helix mimetic compound, VWK603, which effectively targets MDM2 in TNBC cells with lower toxicity than Nutlin-3a.